Jaguar Health reports positive preliminary open — label crofelemer study results in adult short bowel syndrome patients with intestinal failure

Jaguar Health highlighted preliminary findings already presented Oct. 13, 2026 at the ACG meeting from an open-label crofelemer study in adult SBS-IF. Early results showed some patients improved on treatment, with output worsening in several cases once therapy stopped. Safety profile looked favorable, with no significant adverse events reported in participants who completed the protocol. A randomized, double-blind Phase 2 trial in adult Type 1 SBS is underway, with results expected early in the second half of 2027. The intestinal-failure program targets reduced reliance on parenteral support, with an MVID NDA filing planned for mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via (Ref. ID: 202610140900ACCESSWRNAPR_____1236372) on October 14, 2026, and is solely responsible for the information contained therein. (C)